Pay in 4 interest-free payments of $5.74 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Research shows that local intramuscular injection of IGF-1 DES produces localized muscle hypertrophy in the injected muscles without systemic effects on non-injected muscles
Research Background Peptidereceptor interaction studies Biological signalling pathway analysis Comparative peptide behaviour in controlled systems Handling & Reconstitution Reconstitute using bacteriostatic water
This suggests that AOD 9604 may support stable blood sugar without affecting insulin sensitivity
Ipamorelin + CJC-1295 Stack: Evidence, Mechanism, and Protocol At a glance Drug class / Growth hormone secretagogue (GHRP) + Growth hormone-releasing hormone analogue (GHRH analogue) Ipamorelin receptor target / Ghrelin receptor (GHSR-1a), selective, no cortisol or prolactin spike CJC-1295 receptor target / GHRH receptor (GHRHR) on pituitary somatotrophs Combination mechanism / GHRP + GHRH co-stimulation raises GH pulse amplitude 2-to-10-fold over either agent alone in animal models Typical ipamorelin dose / 100-300 mcg subcutaneous injection, 1-3x daily Typical CJC-1295 (no DAC) dose / 100-300 mcg subcutaneous injection, timed with ipamorelin Typical CJC-1295 with DAC dose / 1,000-2,000 mcg subcutaneous injection, once weekly Primary evidence level / Mechanistic + animal + one Phase II RCT (CJC-1295)
Quality of starting material is critical to reproducibility, which is why analytical purity, proper storage, and methodological consistency are emphasized throughout the research workflow
US$ 23.26
US$ 28.10
US$ 27.48
US$ 25.40
US$ 27.92
US$ 26.02
US$ 24.39
